Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
Year: 2006
Type: article
Source: The Lancet
Institutions: University of California, San Francisco, The Heart Research Institute, Universitat de València, Institut Pasteur de Lille, The University of Texas Southwestern Medical Center, The University of Texas at San Antonio Health Science Center, Amsterdam UMC Location University of Amsterdam, University of Amsterdam, State University of New York, Pfizer (United States), University of Glasgow, San Francisco General Hospital
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: atorvastatin, high-intensity statin therapy, metabolic syndrome, coronary artery disease, major adverse cardiovascular events, cardiovascular risk reduction, LDL cholesterol targets, statin dose comparison, cardiovascular mortality, myocardial infarction, stroke, cardiac arrest, NCEP ATP III criteria, secondary prevention, post hoc analysis
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W2114027342
